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Summary  
The effects at two years of polyglactin (Vicryl) mesh inlay and polydioxanone (PDS) 
or polyglactin (Vicryl) suture material on prolapse symptoms, urinary, bowel, sexual 
function and prolapse related quality of life (QoL) in women undergoing pelvic organ 
prolapse surgery were evaluated in a randomised controlled trial with a 2x2 factorial 
design of Vicryl mesh (n=32) or not (n=34) and PDS (n=33) or Vicryl suture (n=33).  
The response rate at two years was 82%.  There were no differences in the prolapse 
symptom scores between the randomised groups.  Prolapse related QoL score 
(mean difference: 2.05, 95% CI 0.19 to 3.91) and urinary incontinence score (mean 
difference: 2.56, 95% CI 0.02 to 5.11) were significantly lower (better) in women who 
had Vicryl compared to PDS sutures.  The apparent superiority of the prolapse-
related QoL and urinary incontinence scores in women using Vicryl suture material 
(versus PDS) needs to be confirmed in a larger trial.   
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INTRODUCTION  
Pelvic organ prolapse (POP) is seen in 50% of parous women (Beck et al., 1991), 
and it affects the woman’s quality of life by its local physical effects and by its effects 
on urinary, bowel or sexual function.  The lifetime risk of having surgery for POP is 
11% (Olsen et al., 1997).  Up to 30% of operations are for recurrent prolapse 
implying that primary surgery has a poor success rate (Olsen et al., 1997; Diez-Itza., 
2007).  This has led gynaecologists to augment prolapse repair with implantation of 
synthetic material (absorbable or non-absorbable synthetic mesh, or biological 
grafts), with the aim of reducing the risk of failure (Jia et al., 2008).   Our hypothesis 
was to test the assumption that mesh would result in less recurrence.   
 
There is limited evidence from the Cochrane review of surgery for prolapse (Maher et 
al., 2010) regarding the use of mesh and also from the systematic review and meta-
analysis by Jia (Jia et al 2008) on the efficacy and safety of using mesh in surgery for 
anterior and /or posterior vaginal wall prolapse.  These two systematic reviews 
reported short term evidence that mesh significantly reduced objective prolapse 
recurrence rates compared with no mesh/graft (Maher et al., 2010, Jia et al 2008).  
However, subjective prolapse symptoms and the impact of surgery on associated 
pelvic floor symptoms such as bladder, bowel and sexual function, quality of life, cost 
and patient satisfaction were poorly reported, and there was little information on 
subsequent surgery for recurrence.  Arguably, these outcomes are of more 
importance to women than clinical observation of recurrence of prolapse (objective 
failure).  Furthermore, patient-reported outcomes are more appropriate than objective 
recurrence because prolapse symptoms are poorly correlated with prolapse stage 
(Srikrishna et al., 2008; Ellerkmann et al., 2001).   
 
There are no trials (other than the current study) comparing different types of sutures 
for prolapse surgery (Maher et al., 2010), and the choice of suture material is also 
controversial.  Polyglactin (Vicryl), a synthetic polyfilament braided suture (size 6-0 
and larger) retains approximately 75% of its tensile strength for two weeks.  At three 
weeks, 50% of its tensile strength is retained and the material is completely absorbed 
by two months.  Polydioxanone (PDS), an absorbable monofilament (single strand) 
suture, maintains 70% of its original tensile strength at two weeks, 50% at four 
weeks, and 25% at six weeks.  Absorption is minimal until about the 90th day 
postoperatively but essentially complete within six months (Dunn DL., 2005; 
Karlovsky et al., 2005).  The theoretical advantages of PDS are its delayed 
absorption providing longer support while native tissue is healing and because it is a 
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monofilament suture, it’s presumed lower risk of post operative infection:  one study 
showed that bacteria were least likely to adhere to PDS compared with any other 
suture materials including Vicryl (Chu et al., 1984).  Our hypothesis was that 
therefore PDS might result in better healing with less infection, and this might result 
in less recurrence.   
 
The aim of this 2x2 factorial feasibility trial was to compare Vicryl inlay mesh with no 
mesh and  PDS (number 2 0) sutures with Vicryl (number 1) sutures for pelvic organ 
prolapse surgery.  We have previously reported the short-term outcomes at 6 months 
(Allahdin et al 2008).  In this paper, we present the patient-reported outcomes using 
the Pelvic Organ Prolapse Symptom Score (POP-SS) and change in quality of life 
(QoL) due to prolapse symptoms at two years after surgery.  In addition we report on 
urinary, bowel and sexual outcomes and their long term effect on condition-specific 
QoL.   
 
MATERIALS AND METHODS 
This feasibility study and its long term follow up were approved by the Grampian 
Research Ethics Committee.  The study protocol was registered in the Controlled 
Trials register in May 2005.  All women admitted for pelvic organ prolapse surgery 
with Stage 2 or more pelvic organ prolapse in the period between May 2005 to 
August 2005 in a single teaching Hospital in North East of Scotland were invited to 
participate in the study.  Eight experienced consultant gynaecologists contributed 
participants to the trial.  Women undergoing concurrent hysterectomy or continence 
procedures were also included.  Eligible women provided informed signed consent to 
both the trial and long term follow-up.  Women were excluded if they were unwilling 
to be randomised or unable to participate in the trial. 
 
Women were randomised to receive Vicryl mesh or not (‘Mesh trial’) and either a 
PDS or Vicryl suture for repair of the pubocervical and /or rectovaginal fascia (‘Suture 
trial’) using a 2 x 2 factorial design.  The design allowed analysis of mesh versus no 
mesh and PDS versus Vicryl sutures as separate trials, as well as exploring potential 
interaction between the two interventions.  Allocation to groups was carried out using 
a secure method of concealment of randomisation (remote computer allocation) on 
the afternoon before surgery.  Both the women and the ward staff were blinded to 
treatment allocation, but blinding of theatre staff and surgeons was not possible.  The 
surgeon performing the operation completed a questionnaire in theatre giving details 
of the operation performed, complications and deviation from allocated treatment 
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(S2). Women completed a preoperative baseline questionnaire (S1) and a 
postoperative questionnaire on the third day after their surgery (S3). Finally they 
were surveyed by postal questionnaire at six months and two years (S4) after 
randomisation, thus avoiding interviewer bias (Figure 1).  A researcher who was blind 
to the allocated procedure conducted the data collection and analysis, using study 
numbers only to identify women and questionnaires.   
 
The primary outcome was women’s rating of prolapse symptoms based on the POP-
SS (Hagen et al., 2009) and QoL due to prolapse symptoms.  Subjective success 
was assessed as women with no residual prolapse symptoms (POP-SS = 0) and no 
residual effect on quality of life due to prolapse symptoms.  Secondary outcomes 
were measured using the International Consultation on Continence (ICI) Short-Form 
Urinary Incontinence questionnaire (Avery et al., 2004), and supplementary bowel 
and sexual symptom questions.  Overall satisfaction was assessed using a five point 
Likert scale, and by the number of women who would recommend prolapse surgery 
to a friend.    
 
Data analysis   
Descriptive statistics were tabulated reporting baseline demographics and clinical 
characteristics.  Mean, standard deviation (SD), median and interquartile range 
(IQR), where appropriate, were reported.   
 
All analyses were based on intention-to-treat (women remained in their allocated 
groups irrespective of receiving allocated treatment).  Analysis of covariance 
(ANCOVA), adjusting for the baseline values where appropriate was used to analyse 
continuous outcomes and logistic regression used to analyse dichotomous 
outcomes.  Where regression analyses were not possible due to small numbers, the 
Mann-Whitney-Wilcoxon or Fisher’s exact test was used.  Interaction between Mesh 
and Suture allocation was examined.  Statistical significance for all endpoints were 
based on two-sided tests with two sided p-value ≤ 0.05 taken as the criterion for 
statistical significance.   
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RESULTS 
Of the 71 eligible women, 66 women were randomised using a 2x2 factorial design 
(Figure 1).There were no significant differences in the patient characteristics between 
the randomised groups before surgery (Table I).  At two years, 54/66 (82%) women 
completed the follow-up questionnaire (Figure 1).   
 
Twelve women failed to return their two year follow-up questionnaire.  We reviewed 
their case records:  two women had died of unrelated causes (cancer:  both had 
received mesh, one was in the Vicryl group and the other in the PDS group).  Of the 
remaining ten, none had any further prolapse operations in Aberdeen, although one 
woman required a transobturator sub-urethral tape procedure for stress urinary 
incontinence.   
 
While the overall POP-SS improved significantly following surgery over time, there 
were no significant differences between the randomised groups in the mean scores 
at two years after adjusting for baseline scores (Table II).  The number of women 
reporting subjective success (assessed as no residual prolapse symptoms) at two 
years in the Mesh trial were:  6/25 (24%) with mesh compared with 8/29 (28%) 
without mesh (p=0.279); in the Suture trial, those who received PDS sutures, 5/26 
(19%) had no residual symptoms compared with 9/28 (32%) who had Vicryl sutures 
(p=0.764).   
 
Similarly, the mean QoL score due to prolapse symptoms improved significantly over 
two years, but there was no evidence of a difference between the groups in the Mesh 
trial at two years after adjusting for baseline scores (Table II).  However, women who 
received PDS sutures had a significantly higher (worse) QoL score at two years 
compared to those receiving Vicryl sutures (Table II).   
 
Repeat prolapse repair operation was performed in five women:  two women from the 
no-mesh group had recurrence at the same site (both had anterior repairs, one with 
PDS sutures and one with Vicryl sutures).  The woman from the PDS suture group 
also had a repair of a de novo posterior prolapse; and three women had a repair of a 
de novo prolapse, two from the mesh group (both with Vicryl sutures) and one from 
the no-mesh group (with PDS sutures).  One other woman, who had a posterior 
repair with PDS suture and no mesh, subsequently had a trans-rectal prolapse 
repaired surgically.   
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In addition, three women required a pessary for recurrent prolapse after surgery:  all 
three were in the mesh group, while two were in the PDS group and one in the Vicryl 
group.   
 
Satisfaction rate and recommendation to a friend 
Overall, 41/48 women (85%) were fairly or very satisfied with their surgery at two 
years, and 41/48 (85%) would recommend the operation to a friend.  However, there 
was no evidence of a difference in the satisfaction rate according to the randomised 
groups (Table III).   
 
 
Urinary symptoms 
At baseline, 49/64 women (77%) were incontinent of urine, and 13 of these 49 
women had a concomitant continence operation (retropubic Tension-free Vaginal 
Tape, Table I).  At two years, 18/22 (82%) women in mesh group were wet compared 
with 16/27 (59%) (p=0.164) in the no mesh group.  Of women who had PDS sutures, 
16/23 (70%) were wet, compared with18/26 (69%) in the Vicryl suture group 
(p=1.00).   
 
Although the differences in incontinence rates did not reach statistical significance, 
when the effect of incontinence on quality of life was assessed, women in whom 
Vicryl sutures were used had significantly better urinary outcomes (versus PDS 
sutures) at two years, whether assessed using the composite ICI incontinence score, 
or a simple quality of life score (Table IV).  There were no corresponding differences 
between the mesh and no mesh groups.   
 
Bowel Symptoms 
There was no evidence of a difference according to the randomised groups in the 
three bowel symptoms or their effect on quality of life (Table V).  The number of 
women with bowel symptoms gradually decreased over time.  Overall at baseline, 30 
(46%) women were constipated sometimes or more often, which decreased to 15 
(29%) at two years.  For faecal urgency, 17 (27%) had symptoms sometimes or more 
often, decreasing to 10 (20%) at two years.  At baseline 13 (20%) women reported 
faecal incontinence occasionally or more often, while at two years, 11 (22%) women 
had it.   
 
 
9 
 
Sexual symptoms and pain 
At two years, 21 women reported being sexually active.  Approximately half started 
within 3 months of surgery, and half later.  Table VI shows that the proportion of 
women with pain during intercourse, and the effect on quality of life due to sexual 
problems was similar in the randomised groups.   
 
Complications  
Two women (3%) experienced short-term complications:  one returned to theatre for 
postoperative bleeding and one women required suprapubic catheterisation for 
urinary retention.  In all, 6/66 (9%) women required stitch removal, and 2/32 (6.3%) 
required removal of some mesh (one before 6 months and one before two years).  At 
two years, 5/51 (10%) had vaginal pain or discomfort which was not related to 
intercourse.     
 
DISCUSSION  
This study describes the follow-up of 66 women two years after prolapse surgery in a 
factorial randomised controlled trial of mesh versus no mesh, and PDS sutures 
versus Vicryl sutures.  This is the only trial which evaluates two different types of 
sutures.   
 
Main message  
Although there was no evidence of a statistically significant difference between the 
randomised groups on the POP-SS or the prevalence of residual prolapse symptoms 
at follow up, women who received Vicryl sutures reported significantly better overall 
quality of life due to prolapse symptoms at two years (mean difference 2.05, 95% CI 
0.19 to 3.91, Table II).   
 
The evidence from three RCTs included in a Cochrane review suggested that the use 
of an absorbable polyglactin mesh (Vicryl) may reduce the objective recurrence of 
prolapse compared with anterior repair alone (Maher at al., 2010). However, patient 
reported outcomes, QoL, patient satisfaction and the re-operation rate for recurrence 
of prolapse were not reported in any of these trials, and follow up was limited to one 
year.  Our study included both patient reported outcomes and a longer term follow 
up.   
 
Meschia et al (Meschia et al., 2007) showed no difference in postoperative urinary 
outcomes (both stress urinary incontinence and overactive bladder) when fascial 
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plication was compared to Pelvicol overlay (porcine dermis graft).  Similarly, no 
difference was noted in the post operative urgency and detrusor overactivity between 
the Prolene mesh (synthetic non-absorbable) and Pelvicol group in one trial 
(Cervigini et al., 2005).  Although there was no difference in the prevalence of urinary 
incontinence at two years between the randomised groups in our study, women 
randomised to the Vicryl suture group had better results on the ICI urinary score and 
quality of life due to urinary symptoms at two years (Table IV).  There were no 
differences in the other dimensions of health (constipation, faecal urgency, faecal 
incontinence, difficulty and pain during intercourse, or satisfaction with surgery) but 
the sample size was small.  We are not aware of any other prolapse surgery trial that 
has reported the effect of mesh or sutures on subsequent urinary, bowel and sexual 
symptoms.  
 
Our reoperation of 6% is comparable to that found in the much larger systematic 
review of the use of Vicryl mesh in prolapse surgery (9%, Jia et al).  Similarly our 
mesh erosion rate of 6% with absorbable synthetic meshes is comparable to the 6% 
reported by Jia et al.   
 
Critical assessment 
The strength of our study is the length of follow up of participants in a prospective 
randomised controlled trial, and the reporting of a range of pelvic floor dysfunction 
symptoms by the women themselves.  The prolapse and urinary symptoms (but not 
bowel or sexual function) were assessed using validated scales (Hagen et al., 2009; 
Avery et al., 2004).   
 
A further strength is the number of gynaecologists who contributed participants.  
There were no learning curve issues as the technique of mesh inlay was a simple 
addition to the standard repair procedure.  The study had high acceptability and 
implementation rates amongst both specialist and general gynaecologists, indicating 
that a larger trial could expect good buy-in, thus increasing its generalisability and 
feasibility.   
 
Because it was a feasibility study, it was not powered to detect differences between 
the groups.  Although some statistically significant differences were found, their 
reliability is uncertain and remains to be confirmed in a larger trial.  While we did not 
examine the women again at two years to assess objective recurrence of prolapse, 
we feel that this is of less importance than the subjective report from the women 
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themselves, or the need for further management (particularly pessaries and surgery) 
which arises as a result of symptomatic recurrence.   
 
We were unable to analyse the data according to type of repair (anterior, posterior or 
both; or primary or secondary surgery) because the sample size was too small, 
although we realise the clinical importance of doing so.  We were unable to report 
differences in the de novo dyspareunia rate, as we did not record the baseline 
dyspareunia rate but we were able to compare women who were actually sexually 
active at follow up according to their randomised allocation.    
 
The apparent differences between the suture types need confirmation and 
explanation.  In fact, in our study, some trends relating to suture type (quality of life 
due to prolapse and urinary incontinence) reached statistical significance in favour of 
Vicryl sutures, contrary to our hypothesis.  However, the clinical significance of the 
apparent benefits from Vicryl suture are difficult to evaluate and need to be confirmed 
in future research.   
 
 
Conclusions 
The current study demonstrated the feasibility of obtaining meaningful patient 
reported outcomes related to prolapse, urinary, bowel and sexual function after 
prolapse surgery in the context of a randomised controlled trial.  The ostensible 
advantages of Vicryl over PDS sutures were unexpected, contrary to our hypothesis, 
and need to be confirmed in future research.  One such study is now under way, the 
multicentre RCT (PROSPECT), which is funded by the UK NIHR NETSCC HTA 
programme.   
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Figure 1 Study Flow chart showing flow of participants through the study 
and 2 years follow up.   
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4 unfit for surgery 
1 declined 
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Table 1  Baseline characteristics by randomised allocation  
 Mesh Trial Suture Trial 
 Mesh (n= 
32) 
No mesh 
(n=34) 
Polydioxanone 
(n=33) 
Polyglactin (n=33) 
     
Age >= 60 years 18 
(56.3%) 
20 (58.8%) 19 (57.6%) 19 (57.6%) 
Parity     
Para 1 or less 15 
(46.9%) 
17 (50%) 14 (42.4%) 18 (54.5%) 
Para 2 or more 17 
(53.1%) 
16 (47.1%) 19 (57.6%) 14 (42.4%) 
     
Post-menopausal 28 
(87.5%) 
28 (82.4%) 28 (84.8%) 28 (84.8%) 
Smoking 1 (3.1%) 3 (8.8%) 3 (9.1%) 1 (3%) 
HRT  5 (15.6%) 2 (5.9%) 2 (6.1%) 5 (15.2%) 
COPD 7 (21.9%) 7 (20.6%) 7 (21.2%) 7 (21.2%) 
PFMT 9 (28.1%) 9 (26.5%) 8 (24.2%) 10 (30.3%) 
Primary operation 27 
(84.4%) 
30 (88.2%) 28 (84.8%) 29 (87.9%) 
Secondary 
operation 
5 (15.6%) 4 (11.8%) 5 (15.2%) 4 (12.1%) 
Preoperative ring 
use 
8 (25%) 4 (11.8%) 4 (12.1%) 8 (24.2%) 
Type of prolapse     
Cystocele 16 (50%) 12 (35.3%) 16 (48.5%) 12 (36.4%) 
Rectocele 7 (21.9%) 6 (17.6%) 5 (15.2%) 8 (24.2%) 
Both (19) 8 (25%) 11 (32.4%) 9 (27.3%) 10 (30.3%) 
Paravaginal 
repair 
2 (6.3%) 0 (0%) 1 (3%) 1 (3%) 
Concomitant 
operations 
    
Hysterectomy 6 (18.8%) 8 (23.5%) 9 (27.3%) 5 (15.2%) 
Cervical 
amputation 
8 (25%) 10 (29.4%) 8 (24.2%) 10 (30.3%) 
Continence 
operation 
7 (21.9%) 6 (17.6%) 5 (15.2%) 8 (24.2%) 
Other 0 (0%) 2 (5.9%) 0 (0%) 2 (6.1%) 
 
 
COPD chronic obstructive airway disease, HRT hormone replacement therapy, PFMT pelvic floor muscle training,  
Polydioxanone = PDS, Polyglactin = Vicryl 
 
 
 
  
Table II     Effects of surgery on prolapse symptom (POP-SS) and Quality of Life (QoL) scores at baseline and 2 years after surgery 
 Mesh Trial  Suture Trial  
 
With Mesh  No mesh  
Adjusted mean 
differencea  
(95% CI) 
With PDS  With Vicryl  
Adjusted mean 
differencea 
(95% CI) 
Baseline 
Mean(SD)n  14.0(7.0) 32      13.0(6.3)34   14.1(7.1)33 13.0(6.2) 33  
2 Years  
Mean(SD)n  4.3(4.2)25      4.3(6.3)29 
0.21 
(-3.14 to 2.73) 5.5(6.3) 26 3.2(4.2)28 2.24(-0.70 to 5.17) 
Quality of Life  due to prolapse symptomsc 
Baseline 
Mean(SD)n  
5.1(3.3)30 4.5(3.8)33   4.7(3.5)31 4.8(3.7)32  
2 Years  
Mean(SD)n 
1.5(3.0)23 1.8(3.5)29 -0.23(-2.08 to 1.63) 2.5(4.1)24 0.9(2.1)28 
 
2.05 (0.19 to 3.91) 
p-value<0.05 
       
 
aThe adjusted mean differences and their confidence intervals were calculated using an ANCOVA model. 
bPOP-SS = Pelvic Organ Prolapse – Symptom Score, (0= none of seven prolapse symptoms were present at any time to 28= when all seven symptoms were 
present all the time) 
c Effect of prolapse symptoms on quality of life (0=‘not at all’ to 10=‘a great deal’). 
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 Table III Number of women satisfied with surgery and number who would recommend surgery to a friend at 2 years after 
surgery 
 Mesh Trial  Suture Trial  
 With Mesh No Mesh p-value a With PDS With Vicryl p-value a 
Satisfied b at 2 years n/N 20/23 21/25 1.000 17/22 24/26 0.289 
Recommend at 2 years n/N 21/24 20/24 1.000 16/22 25/26 0.060 
 
a Fisher’s exact test. 
n= number of women satisfied or recommended surgery to a friend, N = number of women who responded. 
Satisfaction was assessed on a five point Likert scale [very satisfied, fairly satisfied, fairly dissatisfied, very dissatisfied and not sure].   
b Satisfied defined as very or fairly satisfied 
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Table IV  Effects of surgery on urine symptoms and Quality of Life (QoL) scores at baseline and 2 years after surgery 
 
a  The adjusted mean differences and their confidence intervals were calculated through an ANCOVA model. 
 
b ICI-Q score(International Consultation on Continence  Short-Form Urinary Incontinence questionnaire): 0=no symptoms, 21=maximum frequency, quantity 
of incontinence and effect on quality of life 
c  Effect of urinary symptoms on quality of life (0=‘not at all’ to 10=‘a great deal’). 
 Mesh trial  Suture Trial  
 With Mesh No mesh 
Adjusted mean 
difference  a  (95% 
CI) 
With PDS With Vicryl 
Adjusted mean 
differencea 
Effect size 
(95% CI) 
Urinary Symptoms: ICI Score b  
Baseline Mean 
(SD)n 8.1(5.8)32 7.1(6.6)33  6.9(6.0)33 8.3(6.5)32  
2years Mean 
(SD)n  4.2(3.9)25 4.6(5.5)29 
-1.05 
(-3.60 to 1.52) 5.5(5.9)26 3.5(3.3)28 
2.56 
(0.02 to 5.11) 
p-value<0.05 
Quality of Life due to urinary symptoms c  
Baseline Mean 
(SD)n 3.6(3.6)32 3.4(3.7)34  3.1(3.4)33 3.9(4.0)33  
2years  Mean 
(SD)n  1.3(2.6)25 1.5(2.8)29 
-0.38 
(-1.80 to 1.04) 2.1(3.5)26 0.8(1.4)28 
1.45 
(0.03 to 2.86) 
p-value<0.05 
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 Table V  Bowels symptoms and their effect on quality of life at baseline and 2 years after surgery 
 Mesh Trial  Suture Trial  
 With Mesh No Mesh Odds Ratio a 
(95% CI) 
With PDS With Vicryl Odds Ratio a 
(95% CI) 
Constipationc 
Baseline n/N  16/32 14/33  18/33 12/32  
2 years n/N 6/24 9/28 0.70 
(0.21 to 2.38) 
7/24 8/28 1.05 
(0.32 to 3.54) 
Faecal urgencyc 
Baseline n/N 10/31 7/33  9/33 8/31  
2 years n/N 5/24 5/27 1.13 
(0.28 to 4.55) 
5/23 5/28 1.26 
(0.31 to 5.08) 
Faecal incontinencec 
Baseline n/N(%) 8/31 5/33  8/33 5/31  
2 years n/N 5/24 6/27 0.92 
(0.24 to 3.53) 
5/23 6/28 1.03 
(0.237to 3.95) 
Quality of Life due to bowel symptomsd 
   Adjusted mean 
difference b 
(95% CI) 
  Adjusted mean 
difference b 
(95% CI) 
Baseline 
Mean(SD)n 
2.1(2.2)32 1.7(2.2)32  2.1(2.4)33 1.7(2.3)32  
2 years  
Mean(SD)n 
2.0(2.9)23 1.1(2.1)28 0.6 
(-0.77 to 1.98) 
2.2(3.2)23 0.9(1.5)28 1.08 
(-0.29 to 2.45) 
 
n= number of women with bowel symptoms, N = number of women who responded 
a The adjusted odds ratios and their confidence intervals were calculated using a logistic regression model 
bThe adjusted mean differences and their confidence intervals were calculated using an ANCOVA model. 
c Definitions: Constipation [sometimes, most of the time or all the time];  faecal urgency [sometimes, most of the time or all the time];  faecal incontinence 
[occasionally, sometimes, most of the time or all the time].   
d Effect of any bowel symptoms on quality of life (0=‘not at all’ to 10=‘a great deal’). 
 Table VI  Number of sexually active women with difficulty with intercourse or pain with intercourse at two years after prolapse 
surgery, and effect of prolapse on quality of life due to sexual problems. 
 Mesh trial  Suture Trial  
 With Mesh No Mesh p-value a With PDS With Vicryl p-valuea 
Difficulty with intercourse 
2 Years n/N 3/9 6/13 0.873 3/11 6/11 0.386 
Pain with intercourse 
2 Years n/N 3/9 3/12 1 2/11 4/10 1 
 
Sexual quality of life scores at baseline  and 2 years after prolapse surgery  
 
 With Mesh No mesh     p-value b With PDS With Vicryl p-valueb 
Baseline-Median [IQR](n) 6.0[2.0 to 7.0](15) 5.0[2.0 to8.5](20)  6.0[3.0 to10.0](18) 3.0[2.0 to7.0](17)  
2 Years Median [IQR]  (n) 0[0 to 1.0](9) 0[0 to 4.0](14)     0.671 0[0 to 4.00](11) 0[0 to 3.0](12) 0.863 
   
Only 21 women were sexually active after surgery 
n = Number of women reporting difficulty or pain with intercourse, and effect of prolapse on quality of life due to sexual symptoms (0=‘not at all’ to 10=‘a great 
deal’), N = number of women who responded. 
 IQR = interquartile range 
a  Fisher’s exact test 
b Mann-Whitney-Wilcoxon test   
 
 
